The global HIV antivirals market is set for a period of robust growth, with a new forecast predicting its value will climb ...

Patients with HIV who are resistant to all four antiretroviral drug classes face a higher risk for death than those who are ...

Even though oncology segment revenue inched up just 1 percent year over year, the firm lifted full-year expectations slightly ...

The S&P 500 climbed Friday as tech stocks rallied, nearing its all-time closing high. Key Takeaways. The S&P 500 added 0.8% on Friday, Au ...

Stocks in the health-care industry rose as markets grew more confident that U.S. borrowing costs will fall, while companies in the sector pleased investors in their quarterly reports. Gilead Sciences ...

Analysts lift targets for Gilead as HIV sales surge and Yeztugo launch gains traction, supporting a stronger full-year ...

Gilead stock briefly broke out Friday after the biotech company beat second-quarter forecasts amid its newest launch in HIV ...

US Stock Market indexes S&P 500, Nasdaq, and Dow Jones made weekly gains as Gilead Sciences Inc (GILD) and Expedia Group Inc ...

Gilead Sciences (NASDAQ:GILD) announced its second-quarter 2025 earnings and revised annual outlook after the market closed ...

Gilead's PrEP Yeztugo is set to become the pharma's star asset, with GlobalData forecasting of just under $5bn in 2031.

Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) jumped 8.7% in the morning session after the company reported second-quarter 2025 results that topped Wall Street's expectations and ...

THE European Medicines Agency on Friday recommended authorizing a twice-yearly injectable drug “lenacapavir” to prevent HIV and help end the virus’ transmission.